Literature DB >> 21082982

CXCL12 and CXCR4 in bone marrow physiology.

Natalia M Moll1, Richard M Ransohoff.   

Abstract

This article discusses the multiple roles of CXCL12 and its receptor, CXCR4, in bone marrow (BM) hematopoietic stem cell (HSC) development and regulation. CXCL12 interaction with CXCR4 results in effects as varied as cell migration, proliferation and survival or apoptosis. The selective signaling pathways that mediate these varied outcomes are summarized briefly. The CXCL12/CXCR4 pair is crucially involved in homing and repopulation of HSCs in the specific BM niches. Mechanisms of HSC mobilization to the peripheral circulation in response to physiological requests and therapeutic stimulations, as well as recent data on the novel receptor for CXCL12, CXCR7, are reviewed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21082982     DOI： 10.1586/ehm.10.16

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


  41 in total

Review 1.  Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.

Authors:  Ting-Ting Han; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2013-10-22       Impact factor: 4.742

Review 2.  Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?

Authors:  Ann De Becker; Ivan Van Riet
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

3.  Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis.

Authors:  Talibah U Metcalf; Victoria K Baxter; Voraphoj Nilaratanakul; Diane E Griffin
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

4.  Ubiquitin E3 ligase Wwp1 negatively regulates osteoblast function by inhibiting osteoblast differentiation and migration.

Authors:  Lei Shu; Hengwei Zhang; Brendan F Boyce; Lianping Xing
Journal:  J Bone Miner Res       Date:  2013-09       Impact factor: 6.741

5.  i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

Authors:  Katherine Griffiths; Olan Dolezal; Benjamin Cao; Susan K Nilsson; Heng B See; Kevin D G Pfleger; Michael Roche; Paul R Gorry; Andrew Pow; Katerina Viduka; Kevin Lim; Bernadine G C Lu; Denison H C Chang; Thomas Murray-Rust; Marc Kvansakul; Matthew A Perugini; Con Dogovski; Marcel Doerflinger; Yuan Zhang; Kathy Parisi; Joanne L Casey; Stewart D Nuttall; Michael Foley
Journal:  J Biol Chem       Date:  2016-04-01       Impact factor: 5.157

6.  Progesterone modulates endothelial progenitor cell (EPC) viability through the CXCL12/CXCR4/PI3K/Akt signalling pathway.

Authors:  Peng Yu; Zhifei Zhang; Shengjie Li; Xiaolong Wen; Wei Quan; Qilong Tian; Jieli Chen; Jianning Zhang; Rongcai Jiang
Journal:  Cell Prolif       Date:  2016-01-27       Impact factor: 6.831

7.  Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.

Authors:  Anna Ehrlich; Paramita Ray; Kathryn E Luker; Elias J Lolis; Gary D Luker
Journal:  Biochem Pharmacol       Date:  2013-08-22       Impact factor: 5.858

Review 8.  Neuroimmune crosstalk in the pathophysiology of hypertension.

Authors:  Laura Calvillo; Mariela M Gironacci; Lia Crotti; Pier Luigi Meroni; Gianfranco Parati
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

9.  CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin.

Authors:  Antonella Rigo; Michele Gottardi; Ernesto Damiani; Massimiliano Bonifacio; Isacco Ferrarini; Pierluigi Mauri; Fabrizio Vinante
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

10.  Co-culture of hematopoietic stem/progenitor cells with human osteblasts favours mono/macrophage differentiation at the expense of the erythroid lineage.

Authors:  Simona Salati; Gina Lisignoli; Cristina Manferdini; Valentina Pennucci; Roberta Zini; Elisa Bianchi; Ruggiero Norfo; Andrea Facchini; Sergio Ferrari; Rossella Manfredini
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.